Search
for
Sort by
Research 30 of 776
- Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
- JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician
- Efficacy of JAK 1/2 inhibition in the treatment of diffuse non-scarring alopecia due to systemic lupus erythematosus
- Association of JAK 1 and JAK 2 gene polymorphism with alopecia areata risk: a case–control genetic study
- Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
- Evaluation of the level of serum Interleukins (IL-2, IL-4, IL-15 andIL-17) and its relationship with disease severity in patients with alopecia areata
- Successful treatment of severe atopic dermatitis and alopecia universalis with upadacitinib in a 29-year-old male patient
- 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
- UHPLC-Q-Orbitrap HRMS-based Metabolomics and In Silico Studies on 5-α-Reductase, JAK1, JAK2, and JAK3 of <i>Albizia saponaria</i> L.: Application to Alopecia
- 26143 Time to scalp hair, eyebrow, and eyelash improvement in patients with alopecia areata treated with baricitinib in the phase 2 portion of the phase 2/3 BRAVE-AA1 study
- Treatment of moderate-to-severe alopecia areata in adolescents with baricitinib: A retrospective review of 29 patients
- Spotlight in Plastic Surgery: October 2022
- 290 Brepocitinib improves cicatricial alopecia and downregulates key T-helper biomarkers
- At the crossroads of 2 alopecias: Androgenetic alopecia pattern of hair regrowth in patients with alopecia areata treated with oral Janus kinase inhibitors
- The Safety and Efficacy of Tofacitinib in 24 Cases of Pediatric Rheumatic Diseases: Single Centre Experience
- 33774 Baricitinib results in eyebrow and eyelash growth in patients with alopecia areata who do not achieve 20% or less scalp hair loss
- Baricitinib Demonstrates Rapid Action Within Just 2 Months of Treatment in Severe and Unresponsive Alopecia Areata: A Case Report
- Hair regrowth in a patient with central centrifugal cicatricial alopecia after a 2-month trial of baricitinib
- Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
- Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata
- The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm
- Novel TMEM173 Mutation and the Role of Disease Modifying Alleles
- Baricitinib: From Rheumatoid Arthritis to COVID‐19
- Ruxolitinib for the treatment of severe alopecia areata
- STAT5 Activation in the Dermal Papilla Is Important for Hair Follicle Growth Phase Induction
- A novel therapeutic paradigm for patients with extensive alopecia areata
- Treatment of severe alopecia areata with baricitinib
- Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
- The Effect of JAK Inhibitor on the Survival, Anagen Re-Entry, and Hair Follicle Immune Privilege Restoration in Human Dermal Papilla Cells
- Application of Baricitinib in Dermatology